Merck & Co., Inc. (MRK) CEO Rob Davis on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 04/28/22
Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS OutlookBenzinga • 04/28/22
Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growthCNBC • 04/28/22
Merck shares pop premarket after earnings beat as COVID antiviral sales top $3 billionMarket Watch • 04/28/22
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced, or High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)Business Wire • 04/25/22
Merck Announces That Joseph Romanelli Will Lead Merck Human Health International, Effective August 1, 2022Business Wire • 04/20/22
Merck Announces U.S. FDA has Granted Breakthrough Therapy Designation for V116, the Company's Investigational 21-Valent Pneumococcal Conjugate Vaccine, for the Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in AdultsBusiness Wire • 04/14/22